Day: August 8, 2018

  1. Home
  2. Archives: August 2018

Amylyx Pharmaceuticals Doses First Patient in Phase II Clinical Trial of AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals Doses First Patient in Phase II Clinical Trial of AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis  

Recent Posts

  • Apic Bio Announces $40M Series A Financing to Advance Novel Gene Therapies for Rare Genetic Disorders
  • Search for cure against the lethal disease ALS boosted by new investor
  • Orphazyme closes a €14 million Series B Extension
  • Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis
  • Project ALS and Amylyx Enter Collaboration to Test AMX0035

ROBERT BROWN

Scientific Advisory Board